|
|
|
|
|
|||||||
|
Session 62
Poster Session
Pharmacokinetics of Antiretroviral Drugs 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 428-W. | Racial Differences in Clinical Efficacy of Efavirenz-Based Antiretroviral Therapy S. Wegner*1, M. Vahey1, M. Dolan1, M. Wallace1, N. Aronson1, A. Barile1, W. Emmons1, S. Frazier1, K. Stephan1, M. Nau2, S. Piscitelli3, R. Harrigan4, and B. Larder4 1U.S. Military HIV Res. Prog., Rockville, MD; 2Henry M. Jackson Fndn., Rockville, MD; 3Vircolab, Gaithersburg, MD; and 4Virco-UK, Cambridge, UK
| ||
| 429-W. | Single and Multiple Dose Pharmacokinetics (PK) of Stavudine (d4T) from an Extended Release (XR) Formulation in Asymptomatic HIV-Infected Subjects S. Kaul*, A. Swaminathan, D. Behr, P. Nichola, J. Gale, and E. O’Mara Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ
| ||
| 430-W. | Pharmacokinetics (PK) of Stavudine (d4T) Extended Release Formulation Compared with Stavudine Immediate Release (IR) Formulation as Part of Potent Antiretroviral Combination Therapy S. Kaul*1, B. Damle1, J. Gale1, G. McKinely2, L. Slater3, A. Huang4, and H. Brett-Smith1 1Bristol-Myers Squibb Pharmaceutical Res. Inst., Princeton, NJ; 2St. Luke’s-Roosevelt Hosp., New York, NY; 3Univ. of Oklahoma, Oklahoma City; and 4Univ. of Louisville, KY
| ||
| 431-W. | An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination with Efavirenz (EFV) in Healthy Adult Subjects (APV10010) M. B. Wire*1, C. Ballow2, S. Preston3, C. Hendrix4, Y. Lou1, P. Piliero3, and D. S. Stein1 1GlaxoSmithKline, Res. Triangle Park, NC; 2Buffalo Clin. Res. Ctr., NY; 3Albany Med. Coll., NY; and 4Johns Hopkins Univ. Sch. of Med., Baltimore, MD
| ||
| 432-W. | Comparative Pharmacokinetics and Short-Term Safety of Twice Daily (BID) Fortovase/Ritonavir and Invirase/Ritonavir M. Kurowski*1, T. Sternfeld1, A. Hill2, and C. Moecklinghoff3 1HIV-LAB, Auguste-Viktoria Krankenhaus, Berlin, Germany; 2Roche, Welwyn, UK; and 3Roche, Grenzach, Germany
| ||
| 433-W. | Multiple-Dose Kaletra (Lopinavir/Ritonavir) does not Affect the Pharmacokinetics of the CYP2D6 Probe, Desipramine R. Bertz*, C. Foit, Y-L. Chiu, B. Bernstein, S. Boller, J. R. Owen, L. Williams, Q. Ji, C. Renz, A. Hsu, G. R. Granneman, and E. Sun Abbott Labs., Abbott Park, IL
| ||
| 434-W. | An Open-Label Steady State Investigation of the Pharmacokinetics (PK) of Tipranavir (TPV) and Ritonavir (RTV) and their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers (BI 1182.5) S. McCallister*1, J. Sabo1, L. Galitz 2, and D. Mayers 1 1Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT and 2South Florida Bioavailability Clin., Miami, FL
| ||
| 435-W. | Evidence of Systemic P-Glycoprotein (P-gp) Inhibitory Activity in Patients Receiving Twice-Daily Nelfinavir (Viracept) J. Donahue*1, D. Dowdy1, K. K. Ratnam1, J. Price2, J. McKinsey1, D. Unutmaz1, J. Nicotera1, S. Raffanti1,3, M. Becker4, and D. W. Haas1 1Vanderbilt Univ. Sch. of Med., Nashville, TN;2Nashville VA Med. Ctr., TN; 3Comprehensive Care Ctr., Nashville, TN; and 4Agouron Pharmaceuticals, Inc., La Jolla, CA
| ||
| 436-W. | Exploring Theoretical Mechanisms for Lack of Resistance to Lopinavir/Ritonavir (LPV/r) in Antiretroviral (ARV)-Naïve Subjects A. Hsu*, D. Kempf, G. R. Granneman, and E. Sun Abbott Labs., Abbott Park, IL
| ||
| 437-W. | Steady-State Indinavir (Crixivan) Pharmacokinetics in Cerebrospinal Fluid (CSF) and Plasma in Patients Receiving Low-Dose Ritonavir (Norvir), as Determined by Ultra-Intensive CSF Sampling D. W. Haas*1, B. Johnson1, J. Nicotera1, V. L. Bailey1, V. L. Harris1, F. Bowles1, S. Raffanti1,2, T. Finn3, J. Schranz3, A. Saah3, and J. Stone3 1Vanderbilt Univ. Sch. of Med., Nashville, TN; 2Comprehensive Care Ctr., Nashville, TN; and 3Merck Res. Labs, West Point, PA
| ||
| 438-W. | Antiretroviral Distribution in Cerebrospinal Fluid and Viral Resistance in HIV-Infected Patients A. Antinori1, C. F. Perno*1, M. L. Giancola1, F. Forbici1, G. Ippolito1, R. Hoetelmans2, and S. Piscitelli2 1Natl. Inst. of Infectious Diseases, L. Spallanzani, Roma, Italy and 2Tibotec-Virco, Mechelen, Belgium and Rockville, MD
| ||
| 439-W. | Penetration of Lopinavir into the Genital Tract of HIV-1-Infected Men S. Sankatsing*1, D. Burger2, J. Droste2, S. Jurriaans1, J. Lange1, and J. Prins1 1Academic Med. Ctr., Amsterdam, The Netherlands and 2Univ. Med. Ctr. Radboud, Nijmegen, The Netherlands
|
